1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

AstraZeneca Completes The Trial To Support Transition Of Breztri to Next-Generation Propellant

10 Sep 2024
Admin
News Article

AstraZeneca Completes The Trial To Support Transition Of Breztri to Next-Generation Propellant

AstraZeneca completes the clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential

Overview

AstraZeneca has completed the studies that support the first regulatory filings for the transition of Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) to an innovative, next-generation propellant with 99.9% lower Global Warming Potential than propellants used in currently available inhaled medicines.

About Breztri

Breztri is a triple-combination therapy for chronic obstructive pulmonary disease (COPD) and will be the first medicine in AstraZeneca’s portfolio of pressurised-metered dose inhalers (pMDIs) to transition to the new propellant.
Clinical programmes for the transition of AstraZeneca’s wider pMDI portfolio to the new propellant are underway.
While pMDIs contribute less than 0.04% of global greenhouse gas emissions, AstraZeneca is committed to significantly reducing this burden.

Statementr from Co-Ordinating Study Investigator

Omar Usmani, Professor of Respiratory Medicine at Imperial College London and co-ordinating study investigator, said: “Respiratory medicines delivered in pressurised metered-dose inhalers are essential for millions of people living with respiratory disease worldwide, including specific vulnerable populations such as children and the elderly. Transitioning to inhaled respiratory medicines using a propellant with a carbon footprint similar to non-propellant-based inhaled medicines is critical for planetary health in reducing the carbon footprint, while addressing patient needs and healthcare professionals’ ability to achieve optimal clinical outcomes.”

From Bopharmaceuticals R&D Department: AstraZeneca

Sharon Barr, Ph.D, executive vice president, biopharmaceuticals R&D, AstraZeneca, said: “Essential, life-saving medicines delivered to patients by pressurised-metered dose inhalers are the most used treatments in respiratory care and ensuring access to them based on clinical need is critical to optimising patient outcomes. We have now completed the studies that support the first regulatory filings to transition Breztri to the innovative propellant with near-zero Global Warming Potential as part of our commitment to patients and the planet.”

Result Announcement

Results from the studies for Breztri with the next-generation propellant will be shared with regulatory authorities, with first submissions in Europe, the UK and China expected before the end of 2024.

Study on HFO-1234ze

AstraZeneca is studying the medical grade version of HFO-1234ze, a next generation propellant, for use in its portfolio of pMDI medicines.
Data from two phase I studies of systemic and lung bioequivalence were presented at the American Thoracic Society (ATS) 2024 Conference in May, and results from the phase IIIb bronchospasm study are being presented at the European Respiratory Society (ERS) Congress 2024.
Additional data will be presented at forthcoming medical meetings.

Chronic Respiratory Diseases & Medicines

Chronic respiratory diseases including COPD and asthma affect hundreds of millions of people around the world.
Respiratory inhaled medicines delivered by pMDIs account for 78% of inhaler usage globally.
Reducing the carbon impact of pMDIs is a key product-related element of AstraZeneca’s Ambition Zero Carbon strategy, alongside the company’s commitment to improving patient outcomes.
Implementing evidence-based guidelines into clinical practice can reduce exacerbations and hospitalisations, and the resulting improved patient outcomes may also decrease the overall carbon footprint associated with respiratory care.

BGF Approval

Budesonide/glycopyrronium/formoterol fumarate (BGF), approved under the brand name Trixeo Aerosphere in the EU and Breztri Aerosphere in Japan, China and the US, is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, a LABA, glycopyrronium bromide, a LAMA, with budesonide, an ICS, and delivered via the Aerosphere pressurised metered-dose inhaler.
Breztri/Trixeo Aerosphere is approved to treat COPD in more than 50 countries worldwide including the US, EU, China, Japan, and is currently being studied in phase III trials for asthma.

Medical Grade Version of HFO-1234ze

Developed and patented by Honeywell, the medical grade version of HFO-1234ze is a critical propellant to enable the transition of pMDI medicines with reduced climate impact, given its near-zero GWP.
AstraZeneca announced in 2022 its collaboration with Honeywell to develop respiratory inhaled medicines using the new propellant.

AstraZeneca for Decarbonization

Through its Ambition Zero Carbon strategy, AstraZeneca is pursuing bold, science-based decarbonisation targets, accelerating progress towards net zero.
The company is on track to reduce greenhouse gas (GHG) emissions from its global operations and fleet (Scope 1 and 2) by 98% by 2026 (from a 2015 baseline).
AstraZeneca aims to halve its entire value chain footprint (Scope 3) by 2030, on the way to a 90% absolute emissions reduction (from a 2019 baseline) by 2045 at the latest.
By 2030, the company will become carbon negative for all residual emissions.
AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard.

Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals is a key disease area and growth driver to the company.

About AstraZeneca

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.
The company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets.